FDA — authorised 31 May 2005
- Application: BLA125117
- Marketing authorisation holder: BIOMARIN
- Indication: Type 1 - New Molecular Entity
- Status: approved
🇺🇸 Aryplase in United States
FDA authorised Aryplase on 31 May 2005
Marketing authorisation
Aryplase in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in United States
Frequently asked questions
Is Aryplase approved in United States?
Yes. FDA authorised it on 31 May 2005.
Who is the marketing authorisation holder for Aryplase in United States?
BIOMARIN holds the US marketing authorisation.